Acotec Extends Strategic Collaboration with Boston Scientific Group

Acotec Scientific Holdings Limited ( (HK:6669) ) just unveiled an update.

Acotec Scientific Holdings Limited has entered into two significant agreements with its controlling shareholder, Boston Scientific Group Limited (BSG), to extend their collaboration and service arrangements for another three years, from January 1, 2026, to December 31, 2028. These agreements, known as the 2026 Master Collaboration Agreement and the 2026 Master Service Agreement, aim to enhance the cross-selling, distribution, and manufacturing services of Acotec’s products, including new and improved offerings, across various regions. The agreements are classified as continuing connected transactions under the Hong Kong Stock Exchange Listing Rules, requiring independent shareholders’ approval due to the significant percentage ratios involved. This strategic move is expected to strengthen Acotec’s market position and expand its product reach, benefiting stakeholders through improved business synergies and operational efficiencies.

The most recent analyst rating on (HK:6669) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Acotec Scientific Holdings Limited stock, see the HK:6669 Stock Forecast page.

More about Acotec Scientific Holdings Limited

Acotec Scientific Holdings Limited is a company incorporated in the Cayman Islands, operating in the medical device industry. It focuses on the development and commercialization of innovative medical products, including semi-compliant PTCA balloons and Paclitaxel-Eluting Coronary Balloon Dilation Catheters, primarily distributed in the Greater China Region and other regions.

Average Trading Volume: 516,849

Technical Sentiment Signal: Buy

Current Market Cap: HK$3.95B

Learn more about 6669 stock on TipRanks’ Stock Analysis page.